Locations:
Search
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Making sense of the fast-moving treatment landscape
Explaining common misconceptions about chimeric antigen receptor therapy
Clinicians share practices to streamline initiation of care
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Findings from large database important to inform clinical practice
What’s coming up at ASH and beyond
Advertisement
Advertisement